Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough's Temodar Gets Priority Review For First-Line Glioma

This article was originally published in The Pink Sheet Daily

Executive Summary

The supplemental application has a user fee goal date of March 2005. Phase II/III trials of the oral cytotoxic alkylating agent are ongoing for treatment of brain metastases from various cancers.

You may also be interested in...



Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma

Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.

Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma

Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.

Guilford CEO Search Ends With Appointment Of Bristol Exec

Bristol VP-Strategy Dean Mitchell will join Guilford Dec. 1, replacing company co-founder Craig Smith, who is retiring. Mitchell is expected to oversee a busy period for the company, which anticipates results from up to 13 late-stage clinical trials during the next 12-18 months.

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel